Detalles de la búsqueda
1.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Cancer
; 129(1): 118-129, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36308296
2.
A novel patient-reported outcomes instrument assessing the side effects of peanut oral immunotherapy.
Ann Allergy Asthma Immunol
; 126(1): 61-68, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32745610
3.
Real-world persistence with dupilumab among adults with atopic dermatitis.
Ann Allergy Asthma Immunol
; 126(1): 40-45, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32739313
4.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 375(24): 2335-2348, 2016 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27690741
5.
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.
Ann Allergy Asthma Immunol
; 122(1): 41-49.e2, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30138668
6.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28478972
7.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 387(10013): 40-52, 2016 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26454361
8.
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
J Am Acad Dermatol
; 74(3): 491-8, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26777100
9.
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
J Am Acad Dermatol
; 75(3): 506-515, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27268421
10.
Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls.
Clin Pharmacol Ther
; 114(2): 303-315, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37078264
11.
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
Clin Pharmacol Ther
; 114(2): 325-355, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37079433
12.
The Patient Matters in the End(point).
Adv Ther
; 39(11): 4847-4852, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35930125
13.
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database.
BMJ Open
; 12(12): e064953, 2022 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535724
14.
Reliability and Validity of an Instrument of COVID-19 Patient-Reported Symptoms in Outpatients.
JAMA Netw Open
; 5(10): e2239053, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36306132
15.
Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies.
J Patient Rep Outcomes
; 6(1): 41, 2022 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507193
16.
Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients.
BMJ Open
; 12(5): e055989, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35501077
17.
Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.
Front Pharmacol
; 13: 1031992, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36339622
18.
Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.
Infect Dis Ther
; 11(6): 2125-2139, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181639
19.
Cost-effectiveness of PCSK9 Inhibitor Therapy.
JAMA
; 316(20): 2151-2152, 2016 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27893122
20.
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
J Immunother Cancer
; 9(8)2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34413166